Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Oligodendroglioma Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Oligodendroglioma Overview | 9 | 1 |
| Pipeline Products for Oligodendroglioma Comparative Analysis | 10 | 1 |
| Oligodendroglioma Therapeutics under Development by Companies | 11 | 1 |
| Oligodendroglioma Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Oligodendroglioma Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Oligodendroglioma Products under Development by Companies | 15 | 1 |
| Oligodendroglioma Products under Investigation by Universities/Institutes | 16 | 1 |
| Oligodendroglioma Companies Involved in Therapeutics Development | 17 | 11 |
| AngioChem Inc. | 17 | 1 |
| Axelar AB | 18 | 1 |
| Boehringer Ingelheim GmbH | 19 | 1 |
| Bristol-Myers Squibb Company | 20 | 1 |
| Cavion LLC | 21 | 1 |
| Celldex Therapeutics, Inc. | 22 | 1 |
| F. Hoffmann-La Roche Ltd. | 23 | 1 |
| Millennium Pharmaceuticals Inc | 24 | 1 |
| Novartis AG | 25 | 1 |
| Pfizer Inc. | 26 | 1 |
| Tocagen Inc. | 27 | 1 |
| Oligodendroglioma Therapeutics Assessment | 28 | 10 |
| Assessment by Monotherapy Products | 28 | 1 |
| Assessment by Combination Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 75 |
| afatinib dimaleate Drug Profile | 38 | 13 |
| alisertib Drug Profile | 51 | 5 |
| AXL-1717 Drug Profile | 56 | 2 |
| bevacizumab Drug Profile | 58 | 10 |
| CDX-1401 Drug Profile | 68 | 3 |
| Cellular Immunotherapy for Gliomas Drug Profile | 71 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 72 | 1 |
| dasatinib Drug Profile | 73 | 3 |
| DNX-2401 Drug Profile | 76 | 3 |
| flucytosine + TBio-01 Drug Profile | 79 | 1 |
| flucytosine ER + vocimagene amiretrorepvec Drug Profile | 80 | 7 |
| irinotecan hydrochloride + TBio-02 Drug Profile | 87 | 2 |
| mibefradil dihydrochloride Drug Profile | 89 | 3 |
| nilotinib Drug Profile | 92 | 5 |
| p28 Drug Profile | 97 | 2 |
| paclitaxel trevatide Drug Profile | 99 | 4 |
| palbociclib Drug Profile | 103 | 10 |
| Oligodendroglioma Dormant Projects | 113 | 1 |
| Oligodendroglioma Discontinued Products | 114 | 1 |
| Appendix | 115 | 2 |
| Methodology | 115 | 1 |
| Coverage | 115 | 1 |
| Secondary Research | 115 | 1 |
| Primary Research | 115 | 1 |
| Expert Panel Validation | 115 | 1 |
| Contact Us | 115 | 1 |
| Disclaimer | 116 | 1 |